TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24898301

Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy (CBT)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Waiting-list control
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: MBCT and CBT
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: HbA1c levels
Number of subjects: 94
Study: 22045924

Group type: EXPERIMENTAL
Intervention: DPP4 inhibitor, sitagliptin
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 20191713

Group type: EXPERIMENTAL
Intervention: Experimental treatments
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison treatments
Number of subjects: 0
Study: 17590070

Group type: EXPERIMENTAL
Intervention: Second-generation remote emergency medical oxygen (REMO(2)) system
Number of subjects: 6
Study: 15325891

Group type: EXPERIMENTAL
Intervention: 1.0% C31G
Number of subjects: 36

Group type: COMPARATOR
Intervention: Extra Strength Gynol II (3% nonoxynol-9)
Number of subjects: 36
Study: 11449608

Group type: COMPARATOR
Intervention: Cromolyn
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both medications
Number of subjects: 20
Study: 9449907

Group type: EXPERIMENTAL
Intervention: 0.5% podofilox gel
Number of subjects: 326

Group type: COMPARATOR
Intervention: Vehicle gel
Number of subjects: 326
Study: 7637723

Group type: EXPERIMENTAL
Intervention: Ketoconazole (200 mg per day)
Number of subjects: 43

Group type: COMPARATOR
Intervention: No ketoconazole (Control)
Number of subjects: 43
Study: 2699466

Group type: EXPERIMENTAL
Intervention: Doxofylline (400 mg twice daily)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Slow-release theophylline (300 mg twice daily)
Number of subjects: 139
Study: 7135

Group type: EXPERIMENTAL
Intervention: Cimetidine 300 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Cimetidine 100 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Cimetidine 200 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 31236888

Group type: EXPERIMENTAL
Intervention: 7 g of oral DKP daily (Group A)
Number of subjects: 117

Group type: COMPARATOR
Intervention: 1 tablet of Diane‐35 orally daily (Group B)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: 7 g of oral DKP daily plus 1 tablet of Diane‐35 orally daily (Group C)
Number of subjects: 117
Study: 27900771

Group type: EXPERIMENTAL
Intervention: LAP block
Number of subjects: 45

Group type: COMPARATOR
Intervention: TAP block
Number of subjects: 45
Study: 26390350

Group type: EXPERIMENTAL
Intervention: Delefilcon A
Number of subjects: 39
Study: 23378417

Group type: EXPERIMENTAL
Intervention: Cholecalciferol (25,000 IU) therapy every 2 weeks
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 20188537

Group type: EXPERIMENTAL
Intervention: Helical TomoTherapy (HT)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Dynamic Conformal Arc Therapy (DCAT)
Number of subjects: 10
Study: 20014523

Group type: EXPERIMENTAL
Intervention: Physically attractive woman
Number of subjects: 2

Group type: COMPARATOR
Intervention: Unattractive woman
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Physically attractive condition
Number of subjects: 2

Group type: COMPARATOR
Intervention: Unattractive condition
Number of subjects: 2
Study: 17595892

Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg i.v. (administered over 30 min)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Omeprazole 40 mg i.v. (administered over 30 min)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Esomeprazole 80 mg i.v. + 8 mg/h (for 23.5 h)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Omeprazole 80 mg i.v. + 8 mg/h (for 23.5 h)
Number of subjects: 90
Study: 15077462

Group type: COMPARATOR
Intervention: Conventional treatment with loperamide 2‐6 mg/day for 2 months
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Yogic intervention consisting of 12 asanas and Surya Nadi pranayama two times a day for 2 months
Number of subjects: 22
Study: 11172835

Group type: EXPERIMENTAL
Intervention: recombinant FSH (rFSH)
Number of subjects: 578

Group type: COMPARATOR
Intervention: human menopausal gonadotropins (hMG)
Number of subjects: 578
Study: 9707184

Group type: COMPARATOR
Intervention: Antihypertensive therapy before randomization (tPA 9%, placebo 9%)
Number of subjects: 624

Group type: COMPARATOR
Intervention: Antihypertensive therapy after randomization (tPA 24%, placebo 29%)
Number of subjects: 624

Group type: EXPERIMENTAL
Intervention: Antihypertensive therapy after randomization for tPA patients
Number of subjects: 624
Study: 1515758

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 20

Group type: COMPARATOR
Intervention: Reserpine + Frusemide
Number of subjects: 20
Study: 6088252

Group type: EXPERIMENTAL
Intervention: Cimetidine (200 mg)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Cimetidine (400 mg)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Ranitidine (150 mg)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Ranitidine (300 mg)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Triprolidine (10 mg)
Number of subjects: 7
Study: 31533125

Group type: COMPARATOR
Intervention: Under-normal weight group (<25 kg/m2)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Overweight group (25-29.99 kg/m2)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Obese group (≥30 kg/m2)
Number of subjects: 500
Study: 29996734

Group type: EXPERIMENTAL
Intervention: Therapeutic ultrasound and self-performed stretching of the plantar fascia and calf muscles
Number of subjects: 54

Group type: COMPARATOR
Intervention: Sham ultrasound and self-performed stretching of the plantar fascia and calf muscles
Number of subjects: 54
Study: 27619190

Group type: EXPERIMENTAL
Intervention: Benznidazole (5mg/kg/day for 60 days)
Number of subjects: 14

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 14
Study: 23622351

Group type: EXPERIMENTAL
Intervention: Face-to-face (FTF) weight management clinic
Number of subjects: 20

Group type: COMPARATOR
Intervention: Virtual reality (VR) clinic
Number of subjects: 20
Study: 21159021

Group type: EXPERIMENTAL
Intervention: 1 μg·kg(‐1) of clonidine
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 2 μg·kg(‐1) of clonidine
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 3 μg·kg(‐1) of clonidine
Number of subjects: 120
Study: 19525114

Group type: EXPERIMENTAL
Intervention: Tandem stance (TS)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Tandem stance blind folded (TSBF)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Tandem stance on a balance board (TSBB)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Parallel stance (PS)
Number of subjects: 10
Study: 17178490

Group type: EXPERIMENTAL
Intervention: Open surgery (high condylectomy and disc repositioning)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Arthroscopic surgery (lysis, lavage, and capsular stretch)
Number of subjects: 20
Study: 15086603

Group type: EXPERIMENTAL
Intervention: Propranolol (12 patients; group A)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Endoscopic injection sclerotherapy (EIS) (13 patients; group B)
Number of subjects: 25
Study: 11232676

Group type: COMPARATOR
Intervention: 1-week treatment with lansoprazole (30 mg b.i.d.), clarithromycin (500 mg b.i.d.), and amoxycillin (1 g b.i.d.)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: 2-week treatment with lansoprazole (30 mg b.i.d.), clarithromycin (500 mg b.i.d.), and amoxycillin (1 g b.i.d.)
Number of subjects: 142
Study: 10921813

Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pethidine
Number of subjects: 0
Study: 8607560

Group type: EXPERIMENTAL
Intervention: FPANS 200 micrograms twice daily (bd)
Number of subjects: 549

Group type: COMPARATOR
Intervention: FPANS 200 micrograms once daily (od)
Number of subjects: 549
Study: 2790419

Group type: EXPERIMENTAL
Intervention: 99Tcm‐nanocolloid scintigraphy
Number of subjects: 19

Group type: COMPARATOR
Intervention: Conventional skeletal scintigraphy
Number of subjects: 19

Group type: COMPARATOR
Intervention: 99Tcm‐HMDP two-phase bone scintigraphy
Number of subjects: 19
Study: 1071608

Group type: EXPERIMENTAL
Intervention: Diuretic treatment with metolazone or hydrochlorothiazide
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control period (before treatment)
Number of subjects: 26
Study: 30474376

Group type: EXPERIMENTAL
Intervention: Multilevel church-based intervention including sermons, educational handouts, vegetable and fruit gardens, cooking and nutrition classes, daily mobile messaging, community mapping, and policy changes over 5 months.
Number of subjects: 268

Group type: COMPARATOR
Intervention: Control group (not explicitly detailed in the abstract).
Number of subjects: 268
Study: 28546097

Group type: EXPERIMENTAL
Intervention: Denosumab 60 mg subcutaneous every 6 months for 3 years (long-term group)
Number of subjects: 7808

Group type: EXPERIMENTAL
Intervention: Denosumab 60 mg subcutaneous every 6 months for 3 years (crossover group)
Number of subjects: 7808

Group type: EXPERIMENTAL
Intervention: Denosumab 60 mg subcutaneous every 6 months for 3 years (both groups)
Number of subjects: 7808

Group type: COMPARATOR
Intervention: Placebo for 3 years (control group)
Number of subjects: 7808
Study: 24897394

Group type: EXPERIMENTAL
Intervention: Oxytocin administered after placenta separation (Group 1)
Number of subjects: 178

Group type: COMPARATOR
Intervention: Oxytocin administered after delivery of the shoulder (Group 2)
Number of subjects: 178
Study: 23939510

Group type: EXPERIMENTAL
Intervention: Collaborative care depression management
Number of subjects: 205

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 205
Study: 21570033

Group type: EXPERIMENTAL
Intervention: Aquatic vertical traction
Number of subjects: 98

Group type: COMPARATOR
Intervention: Land-based supine flexion
Number of subjects: 98
Study: 19575235

Group type: EXPERIMENTAL
Intervention: Toltrazuril (Baycox 5% suspension)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Diclazuril
Number of subjects: 145

Group type: COMPARATOR
Intervention: Untreated control
Number of subjects: 145
Study: 18396608

Group type: EXPERIMENTAL
Intervention: Pre-packaging antimalarial drugs and counselling
Number of subjects: 436

Group type: COMPARATOR
Intervention: Counselling but no pre-packaging (Control group A)
Number of subjects: 436

Group type: COMPARATOR
Intervention: Neither counselling nor pre-packaging (Control group B)
Number of subjects: 436
Study: 12782973

Group type: EXPERIMENTAL
Intervention: Manual endplay assessment with spinal manipulation
Number of subjects: 104

Group type: COMPARATOR
Intervention: Sham manipulation (control group)
Number of subjects: 104
Study: 11798728

Group type: EXPERIMENTAL
Intervention: H(2) strain vaccine
Number of subjects: 12036

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 12036
Study: 9371077

Group type: EXPERIMENTAL
Intervention: Herbal remedies
Number of subjects: 0
Study: 7950211

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CTX) and Traditional Chinese Medicine (TCM)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group with same western medicine but no TCM
Number of subjects: 41
Study: 2906458

Group type: EXPERIMENTAL
Intervention: Roxatidine acetate, 75 mg twice daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Roxatidine acetate, 150 mg at bedtime
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Roxatidine acetate, 150 mg after evening meal
Number of subjects: 0
Study: 28857576

Group type: EXPERIMENTAL
Intervention: App-based intervention (Mindtastic Body Dissatisfaction app) with a brief counseling session and 14 days of training
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: App-based intervention (Mindtastic Body Dissatisfaction app)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Wait list group (control)
Number of subjects: 53
Study: 25837277

Group type: EXPERIMENTAL
Intervention: Rhodiola rosea
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57

Group type: COMPARATOR
Intervention: Sertraline vs Placebo
Number of subjects: 57

Group type: COMPARATOR
Intervention: Rhodiola rosea vs Placebo
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 57
Study: 23295630

Group type: EXPERIMENTAL
Intervention: Short-term supportive psychodynamic therapy (PDT)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Antidepressants
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Combined treatment (PDT + Antidepressants)
Number of subjects: 103
Study: 21481164

Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Number of subjects: 134

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 134
Study: 19221060

Group type: EXPERIMENTAL
Intervention: 3D ultrasonography (US) enhanced with a perflubutane microbubble contrast agent
Number of subjects: 139

Group type: COMPARATOR
Intervention: 3D contrast-enhanced multidetector CT
Number of subjects: 139
Study: 16536197

Group type: EXPERIMENTAL
Intervention: Prime & Bond NT (Dentsply)
Number of subjects: 15

Group type: COMPARATOR
Intervention: 37% phosphoric acid + Prime & Bond NT
Number of subjects: 15

Group type: COMPARATOR
Intervention: Non-Rinse Conditioner (Dentsply) + Prime & Bond NT
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Non-Rinse Conditioner (Dentsply) + Prime & Bond 2.1 (Dentsply)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Prompt L‐Pop (3M ESPE)
Number of subjects: 15
Study: 12485381

Group type: EXPERIMENTAL
Intervention: Maximum voluntary clench (MVC) with a single 200-microm occlusal interference positioned on teeth 16, 13, 23, 26
Number of subjects: 30

Group type: COMPARATOR
Intervention: MVC in intercuspal position
Number of subjects: 30
Study: 10690389

Group type: EXPERIMENTAL
Intervention: Whole abdominal radiotherapy 2.250 rads in ten fractions
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Melphalan 8 mg/m2/d x 4 weeks x 18 courses
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Intraperitoneal chromic phosphate 10‐20 mCi
Number of subjects: 257

Group type: COMPARATOR
Intervention: Age-matched controls
Number of subjects: 257
Study: 9505838

Group type: EXPERIMENTAL
Intervention: T2 weighted fat suppressed turbo spin echo (T2W SPIR)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Gadolinium-enhanced T1 weighted spin echo (Gd-T1W SE)
Number of subjects: 36
Study: 8438599

Group type: EXPERIMENTAL
Intervention: Prostacyclin (PGI2) and Molsidomine (ML)
Number of subjects: 20
Study: 3887254

Group type: EXPERIMENTAL
Intervention: Single dose of trimethoprim
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Single dose of co-trimoxazole
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Single dose of amoxycillin
Number of subjects: 4

Group type: COMPARATOR
Intervention: Five-day course of trimethoprim
Number of subjects: 4
Study: 31076331

Group type: EXPERIMENTAL
Intervention: Traditional fully crossed design for four noise reduction methods
Number of subjects: 10

Group type: COMPARATOR
Intervention: Pseudoreader design using paired reader performances
Number of subjects: 10
Study: 29762737

Group type: EXPERIMENTAL
Intervention: Postnatal lifestyle intervention program (1-hour educational program, 3-month referral to Slimming World, pedometer, structured telephone and text support)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Postnatal lifestyle intervention program
Number of subjects: 60
Study: 26725450

Group type: EXPERIMENTAL
Intervention: High-dose vaccine (5×10^10 viral particles)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Low-dose vaccine (2.5×10^10 viral particles)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 24431901

Group type: EXPERIMENTAL
Intervention: Intracoronary administration of autologous bone marrow-derived mesenchymal stem cells (MSCs)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study: 23291996

Group type: EXPERIMENTAL
Intervention: Participatory weight-loss program
Number of subjects: 24
Study: 21406629

Group type: EXPERIMENTAL
Intervention: 320‐detector CT
Number of subjects: 154

Group type: COMPARATOR
Intervention: 64‐detector CT
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 154
Study: 18251758

Group type: EXPERIMENTAL
Intervention: Oral administration of 0.1 mg imidafenacin
Number of subjects: 14

Group type: COMPARATOR
Intervention: Intravenous infusion of 0.028 mg imidafenacin
Number of subjects: 14
Study: 16855626

Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment
Number of subjects: 6066

Group type: EXPERIMENTAL
Intervention: Two classes of antihypertensive medication
Number of subjects: 6066

Group type: EXPERIMENTAL
Intervention: Three or more classes of antihypertensive medication
Number of subjects: 6066

Group type: EXPERIMENTAL
Intervention: Doctor diagnosis of hypertension and taking antihypertensive medication
Number of subjects: 6066
Study: 12826782

Group type: EXPERIMENTAL
Intervention: atenolol
Number of subjects: 1292

Group type: EXPERIMENTAL
Intervention: prazosin
Number of subjects: 1292

Group type: COMPARATOR
Intervention: hydrochlorothiazide, diltiazem-SR, captopril, clonidine, prazosin
Number of subjects: 1292

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1292
Study: 10389204

Group type: EXPERIMENTAL
Intervention: Point of Care Testing (POCT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Laboratory Testing
Number of subjects: 0
Study: 9082840

Group type: EXPERIMENTAL
Intervention: Innogem (300 mg)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Lopid (300 mg)
Number of subjects: 19
Study: 1900977

Group type: EXPERIMENTAL
Intervention: Intravenous recombinant tissue‐type plasminogen activator (100 mg over 3 hours, group A)
Number of subjects: 223

Group type: COMPARATOR
Intervention: Conventional medical treatment (group B)
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Coronary arteriography in patients with a patent infarct‐related artery
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Coronary arteriography in patients with an occluded infarct‐related artery
Number of subjects: 223
Study: 7011469

Group type: EXPERIMENTAL
Intervention: sulpiride (600-1,800 mg/day)
Number of subjects: 38

Group type: COMPARATOR
Intervention: trifluoperazine (15-45 mg/day)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: sulpiride
Number of subjects: 38
Study: 30718125

Group type: EXPERIMENTAL
Intervention: mAGIC intervention
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 104
Study: 28640076

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 25869815

Group type: EXPERIMENTAL
Intervention: Naftopidil (75 mg once in the morning and placebo twice a day)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Flopropione (80 mg three times a day)
Number of subjects: 92
Study: 24005170

Group type: EXPERIMENTAL
Intervention: Intratympanic steroid injection (ITS)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (HBO)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Combined ITS and HBO
Number of subjects: 103

Group type: COMPARATOR
Intervention: Control group (no salvage therapies)
Number of subjects: 103
Study: 20601033

Group type: EXPERIMENTAL
Intervention: Initial systemic treatment for cGVHD
Number of subjects: 116
Study: 19372432

Group type: EXPERIMENTAL
Intervention: Self-affirming writing assignments
Number of subjects: 416
Study: 17987458

Group type: EXPERIMENTAL
Intervention: Educational intervention using feminist pedagogical methods
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group of women of similar age from the same community
Number of subjects: 0
Study: 15037273

Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal coronary angioplasty with stenting (PCI, stenting)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Off-pump coronary artery bypass grafting (surgery)
Number of subjects: 102
Study: 11333843

Group type: COMPARATOR
Intervention: 12 mg x kg(‐1) x d(‐1) lysine intake
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 20 mg x kg(‐1) x d(‐1) lysine intake
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 28 mg x kg(‐1) x d(‐1) lysine intake
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 36 mg x kg(‐1) x d(‐1) lysine intake
Number of subjects: 16
Study: 9203720

Group type: EXPERIMENTAL
Intervention: Combined schedule of OPV at birth and both OPV and IPV at 6, 10, and 14 weeks of age
Number of subjects: 1685

Group type: COMPARATOR
Intervention: OPV at birth and at 6, 10, and 14 weeks of age
Number of subjects: 1685

Group type: COMPARATOR
Intervention: Placebo at birth followed by IPV at 6, 10, and 14 weeks of age
Number of subjects: 1685
Study: 7960503

Group type: EXPERIMENTAL
Intervention: Trichoriboside
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Trichosaccharide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (unaffected men)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Trichoriboside and Trichosaccharide
Number of subjects: 0
Study: 3113290

Group type: EXPERIMENTAL
Intervention: Epidural morphine, 4 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Epidural buprenorphine, 0.15 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Epidural buprenorphine, 0.3 mg
Number of subjects: 6
Study: 31838223

Group type: EXPERIMENTAL
Intervention: Anodal tDCS of the dlPFC
Number of subjects: 100

Group type: COMPARATOR
Intervention: Cerebellar tDCS (anodal and cathodal)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 100

Group type: COMPARATOR
Intervention: Cathodal tDCS of the dlPFC
Number of subjects: 100

Group type: COMPARATOR
Intervention: Anodal tDCS of the cerebellum
Number of subjects: 100

Group type: COMPARATOR
Intervention: Cathodal tDCS of the cerebellum
Number of subjects: 100
Study: 29055883

Group type: EXPERIMENTAL
Intervention: Movement control injury prevention exercise programme
Number of subjects: 81

Group type: COMPARATOR
Intervention: Normal practice exercises (control)
Number of subjects: 81
Study: 27318048

Group type: EXPERIMENTAL
Intervention: High ligation and stripping with and without patch saphenoplasty
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: DUS pattern (junctional, nonjunctional, mixed)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: DUS features
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Early ultrasound recurrence
Number of subjects: 130